In 2022, an estimated 11·7 million people were affected by chronic hepatitis C virus (HCV) infection in the WHO Eastern Mediterranean Region (EMR), accounting for 23% of the global burden.1 This ...

Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is one of the growth stocks that could double by 2027. On June 25, the company ...

In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Discover a study comparing HBV- and alcohol-related ACLF, highlighting distinct clinical profiles and the need for aetiology-specific treatment strategies.

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

The incidence in South Asia is rising, and the burden on Africa remains serious. Prevention and treatment of hepatitis B-associated cirrhosis in children and adolescents should not be ignored.

Understanding the structure of the virus is necessary for understanding viral transmission, something Joyce said is not well understood.

AAV204, a novel AAV capsid from the AIM™ capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve ...

Hepatitis B virus (HBV) infection is known to be associated with the risk of hepatocellular carcinoma (HCC), but how and why they are connected remains unknown.